WEATHER ALERT January 27, 2026 (12:00 PM): Due to the recent inclement weather, we are experiencing higher than usual call volume. Your call is important to us. We strongly recommend current patients utilize the Patient Portal to reach their clinical teams with questions or to adjust their appointment if necessary. Messages received in the Patient Portal will be returned as quickly as possible. Thank you for your patience.
A polysulphonated naphthylurea with potential antineoplastic activity. Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration. This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
